FDA approves Galderma’s Nemluvio to treat atopic dermatitis
Pharmaceutical Technology
DECEMBER 16, 2024
The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.
Mon.Dec 16, 2024
130 
Abnormal Patterns in Brain Waves May Indicate ADHD, Expert Says
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 16, 2024
Children with attention deficit hyperactivity disorder ( ADHD) do not have a behavioural disorder, nor are they lazy, or lacking in manners and boundaries. Their brains mature in a different way, with different patterns of neurological activity and a number of neurochemical differences. For this reason, ADHD is considered to be a neurodevelopmental disorder.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ADCs breach barriers to become mainstream cancer treatment
Pharmaceutical Technology
DECEMBER 16, 2024
Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance
Pharma Mirror
DECEMBER 16, 2024
CPHI Milan the worlds largest pharma event hosted last month in Milan saw a new record attendance of 59,000 pharma executives buoyed by returning confidence and increased deal-making on site. The post Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance appeared first on Pharma Mirror Magazine.
The future of third-party logistics in an evolving biopharmaceutical world
Pharmaceutical Technology
DECEMBER 16, 2024
The biopharmaceutical industry faces a future full of risks and rewards. But what role will 3PL suppliers play?
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Denmark’s HTA evolution
Pharmaceutical Technology
DECEMBER 16, 2024
New HTA statistics produced by Denmarks Medicinrdet for 2024 have prompted GlobalData to assess evolving HTA trends in the Nordic market.
Are we overlooking something critical in cell and gene therapy research?
Bio Pharma Dive
DECEMBER 16, 2024
EMA recommends expanding approval of Ofev to children and adolescents
Pharmaceutical Technology
DECEMBER 16, 2024
Boehringer Ingelheims blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.
Small cell lung cancer: Navigating the global clinical trial landscape
Pharmaceutical Technology
DECEMBER 16, 2024
Discover the latest advancements in small cell lung cancer through Novotech CROs in-depth disease analysis.
Reprieve for WuXi as Biosecure vote likely pushed to 2025
Pharmaceutical Technology
DECEMBER 16, 2024
WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
EMA CHMP recommends Lilly’s Crohn’s therapy for EU approval
Pharmaceutical Technology
DECEMBER 16, 2024
The EMA's CHMP has recommended Lillys Omvoh (mirikizumab) for approval in the EU to treat Crohn's disease.
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
Bio Pharma Dive
DECEMBER 16, 2024
AbbVie to acquire Nimble Therapeutics for $200m
Pharmaceutical Technology
DECEMBER 16, 2024
AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Checkpoint Therapeutics takes on Merck's mighty Keytruda with FDA approval for Unloxcyt in skin cancer
Fierce Pharma
DECEMBER 16, 2024
CSL receives positive opinion for garadacimab in hereditary angioedema
Pharma Times
DECEMBER 16, 2024
New treatment could revolutionise care for HAE patients
Beckley Psytech announces positive results for ELE-101 in depression trial
Pharma Times
DECEMBER 16, 2024
Phase 2a study shows promising antidepressant effects
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
FDA blesses atopic dermatitis label expansions for Organon's Vtama, Galderma's Nemluvio
Fierce Pharma
DECEMBER 16, 2024
HeartBeam’s Credit Card-Sized Cardiac Monitor Cleared for At-Home Use
XTalks
DECEMBER 16, 2024
Imagine having a heart monitoring device small enough to fit in a purse or a wallet, ready to record critical heart data whenever symptoms arise. This device by HeartBeam, Inc. is a breakthrough in at-home cardiac care, allowing patients to capture high-quality electrocardiograms (ECGs) wherever they are. When symptoms occur, patients simply place the device on their chest and follow prompts from a companion app.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
The Beatles Revolutionized the Music Industry by Using Recording Studios — Will AI Revolutionize the Medical Writing Industry Next?
XTalks
DECEMBER 16, 2024
Maria Hopfgarten Head of Global Medical Writing PPD Clinical Research Business of Thermo Fisher Scientific Artificial intelligence (AI) is revolutionizing industries worldwide, and medical writing is no exception. With the integration of human intelligence (HI) with AI, the field is discovering new efficiencies and maintaining, or even improving, the rigor required for quality and compliance.
Novo Nordisk blueprints $1.2B rare disease production plant in Denmark, where it plans to hire on 400 new staffers
Fierce Pharma
DECEMBER 16, 2024
Trade & Channel Strategies 2024: A GTN Bubble Balancing Act
Pharmaceutical Commerce
DECEMBER 16, 2024
A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.
Neurocrine's Crenessity ends 70-year drought with FDA nod for rare genetic disease
Fierce Pharma
DECEMBER 16, 2024
Let's personalize your content